Anidulafungin--state of affairs from a clinical perspective.

about

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus.

P2860

Q37864429-84492D65-7373-4CDE-A4CA-87A931BFB485 Q42740228-557594E0-F838-4343-992E-F0F563BBAACD

P2860

Anidulafungin--state of affairs from a clinical perspective.

Item

http://www.wikidata.org/entity/Q36774257

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Anidulafungin--state of affairs from a clinical perspective.

@ast

Anidulafungin--state of affairs from a clinical perspective.

@en

type

Item

label

Anidulafungin--state of affairs from a clinical perspective.

@ast

Anidulafungin--state of affairs from a clinical perspective.

@en

prefLabel

Anidulafungin--state of affairs from a clinical perspective.

@ast

Anidulafungin--state of affairs from a clinical perspective.

@en

P1476

Anidulafungin--state of affairs from a clinical perspective

@en

P2093

Jörg J Vehreschild

http://www.w3.org/2001/XMLSchema#string

Meinolf Karthaus

http://www.w3.org/2001/XMLSchema#string

Tim Kümmerle

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis

Echinocandin antifungal drugs

Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.

Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.

Invasive oesophageal candidiasis: current and developing treatment options.

Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis

P304

38-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1439-0507.2007.01378.X

http://www.w3.org/2001/XMLSchema#string

P478

50 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Oliver A Cornely

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17394608

http://www.w3.org/2001/XMLSchema#string

Anidulafungin--state of affairs from a clinical perspective.

about

P2860

P2860

Anidulafungin--state of affairs from a clinical perspective.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698